Jonathan Drachman - Seagen President
| SGENDelisted Stock | USD 228.74 0.19 0.08% |
President
Dr. Jonathan G. Drachman, M.D. was Chief Medical Officer, Executive Vice President Research and Development of the Company. He has served as our Chief Medical Officer and Executive Vice President, Research and Development since October 2013. Dr. Drachman previously served as our Senior Vice President, Research and Translational Medicine and various other positions of increasing authority. Prior to joining Seattle Genetics in November 2004, Dr. Drachman was Associate Professor in the Hematology Division, Department of Medicine at the University of Washington in Seattle, where he remains a Clinical Associate Professor of Medicine. He also served as Senior Investigator in the Division of Research and Education and Medical Director of the Umbilical Cord Blood Program at the Puget Sound Blood Center. Dr. Drachman also serves as a director of Calithera Biosciences, Inc., a publiclytraded biotechnology company since 2013.
| Age | 54 |
| Tenure | 11 years |
| Phone | 425 527 4000 |
| Web | https://www.seagen.com |
Jonathan Drachman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jonathan Drachman against Seagen stock is an integral part of due diligence when investing in Seagen. Jonathan Drachman insider activity provides valuable insight into whether Seagen is net buyers or sellers over its current business cycle. Note, Seagen insiders must abide by specific rules, including filing SEC forms every time they buy or sell Seagen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jonathan Drachman over a month ago Acquisition by Jonathan Drachman of 415 shares of Harpoon Therapeutics subject to Rule 16b-3 |
Seagen Management Efficiency
The company has return on total asset (ROA) of (0.1294) % which means that it has lost $0.1294 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2793) %, meaning that it created substantial loss on money invested by shareholders. Seagen's management efficiency ratios could be used to measure how well Seagen manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 43.47 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Seagen Inc has a current ratio of 4.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Seagen until it has trouble settling it off, either with new capital or with free cash flow. So, Seagen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Seagen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Seagen to invest in growth at high rates of return. When we think about Seagen's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Daniel Spiegelman | Biomarin Pharmaceutical | 58 | |
| Al Kildani | Halozyme Therapeutics | N/A | |
| Sunil Agarwal | Ultragenyx | 46 | |
| Yvonne Greenstreet | Alnylam Pharmaceuticals | 55 | |
| Christopher Senner | Exelixis | 56 | |
| Gisela Schwab | Exelixis | 61 | |
| Alan Eisenberg | Alnylam Pharmaceuticals | N/A | |
| Manmeet Soni | Alnylam Pharmaceuticals | 40 | |
| Peter Smith | Alnylam Pharmaceuticals | 58 | |
| Karah Parschauer | Ultragenyx | 40 | |
| Steven Stein | Incyte | 51 | |
| Eric Siegel | Incyte | 51 | |
| Rebecca Taub | Madrigal Pharmaceuticals | 66 | |
| David Gryska | Incyte | 61 | |
| Lotte Soenderbjerg | Ascendis Pharma AS | 52 | |
| Camille Bedrosian | Ultragenyx | 65 | |
| Nicole Perry | Apellis Pharmaceuticals | 53 | |
| Scott Smith | Ascendis Pharma AS | 50 | |
| Jeffrey Hessekiel | Exelixis | 49 | |
| John Pinion | Ultragenyx | 52 | |
| Lukas Scheibler | Apellis Pharmaceuticals | 47 | |
Management Performance
| Return On Equity | -0.28 | |||
| Return On Asset | -0.13 |
Seagen Inc Leadership Team
Elected by the shareholders, the Seagen's board of directors comprises two types of representatives: Seagen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seagen. The board's role is to monitor Seagen's management team and ensure that shareholders' interests are well served. Seagen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seagen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Dansey, Chief Medical Officer | ||
| Vaughn Himes, Executive VP of Process Sciences and Technical Operations | ||
| Daniel Welch, Independent Director | ||
| Felix Baker, Lead Independent Director | ||
| Nancy Simonian, Independent Director | ||
| Peggy Pinkston, IR Contact Officer | ||
| Charles Romp, Ex US | ||
| MS JD, Chief Officer | ||
| Darren Cline, Executive Vice President - Commercial | ||
| Eric Dobmeier, COO, Corporate Secretary | ||
| Todd Simpson, CFO and Principal Accounting Officer | ||
| Pinkston Peggy, Senior Director - Corporate Communications | ||
| David Gryska, Independent Director | ||
| David Caouette, VP Communications | ||
| Srinivas Akkaraju, Independent Director | ||
| Alpna Seth, Director | ||
| Matt Skelton, VP Marketing | ||
| Marc Lippman, Independent Director | ||
| Jonathan Drachman, Chief Medical Officer and Executive Vice President Research and Development | ||
| Jean Liu, Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary | ||
| Robert Lechleider, Senior Vice President - Clinical Development | ||
| Christopher Pawlowicz, Ex HR | ||
| Clay Siegall, Co-Founder, Chairman, CEO and Pres | ||
| Robin Taylor, Chief Commercial Officer | ||
| Dennis Benjamin, Senior Vice President - Translational Research | ||
| Roger MD, Pres RD | ||
| John Orwin, Director | ||
| John McLaughlin, Independent Director |
Seagen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Seagen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.28 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.33) % | |||
| Operating Margin | (0.35) % | |||
| Current Valuation | 42.06 B | |||
| Shares Outstanding | 188.66 M | |||
| Shares Owned By Insiders | 0.81 % | |||
| Shares Owned By Institutions | 88.82 % | |||
| Number Of Shares Shorted | 9.58 M | |||
| Price To Earning | 32.75 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Seagen Inc information on this page should be used as a complementary analysis to other Seagen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Seagen Stock
If you are still planning to invest in Seagen Inc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Seagen's history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |